8-K: Turn Therapeutics Reports Q3 2025, NASDAQ Debut & Medline Deal

Turn Therapeutics announced its third quarter 2025 financial results, highlighted by its NASDAQ listing, new board appointments, and a significant global agreement with Medline.

Summary

• Reported financial and operating results for the third quarter ended September 30, 2025.
• Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025.
• Entered into a global supply, development, and license agreement with Medline, a leading medical-surgical product manufacturer and distributor.
• Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester.
• Appointed Andrew Scott as Vice President of Corporate Communications.
• Demonstrated extended stability for the Intranasal Vaccine Program, showing 14 days of viability at ambient temperature and 28 days under standard refrigeration.
• Commenced a clinical trial for the first topical IL-36/IL-31 inhibitor for Eczema.
• Net loss for the three months ended September 30, 2025, was $(1,904,184), compared to $(666,442) for the same period in 2024.
• General and Administrative (G&A) expenses increased by $1.2 million to $1.75 million in Q3 2025, primarily due to costs related to the Nasdaq direct listing.
• Cash and cash equivalents stood at $3.11 million as of September 30, 2025.

Sentiment

Score: 6

Explanation: While financial losses increased due to listing costs, the company achieved significant strategic milestones including a NASDAQ listing, a major partnership with Medline, and advancements in its clinical pipeline and management team. These strategic positives outweigh the expected increase in G&A expenses associated with becoming a public company, indicating a moderately positive outlook for future growth and funding opportunities.

Positives

• Successful NASDAQ listing on October 8, 2025, providing access to public market funding to fuel growth.
• Strategic global supply, development, and license agreement with Medline, expected to generate revenues without significant capital investment and offset some costs.
• Strengthening of the Board of Directors with the appointments of experienced professionals Arthur Golden and Dr. Kent Kester.
• Appointment of Andrew Scott as VP of Corporate Communications, bringing over 30 years of capital markets and corporate finance experience.
• Positive stability data for the Intranasal Vaccine Program, demonstrating 14 days of viability at ambient temperature and 28 days under standard refrigeration.
• Commencement of a clinical trial for a topical IL-36/IL-31 inhibitor for Eczema, building on extensive prior in-human uses and in-vivo data.
• Improvement in total stockholders' equity from a deficit of $(177,432) as of December 31, 2024, to $504,019 as of September 30, 2025.

Negatives

• Net loss for the third quarter of 2025 significantly increased to $(1,904,184) from $(666,442) in the third quarter of 2024.
• General and Administrative (G&A) expenses rose substantially by $1.2 million to $1.75 million in Q3 2025, primarily due to legal, advisory, and other fees related to the Nasdaq direct listing.
• Basic and diluted net loss per common share increased to $(0.07) in Q3 2025 from $(0.03) in Q3 2024.

Risks

• Risks related to the timing and effectiveness of the Company's registration statement.
• Risks related to the success of development programs.
• Risks related to the Company's ability to execute its strategic plan.
• General risks and uncertainties that could cause actual results to differ from forward-looking statements, as detailed in the Company's SEC filings.

Future Outlook

The company anticipates seeing data from its lead program in moderate to severe eczema in early 2026, which will inform its development pathway. It also plans to continue developing global relationships to leverage its PermaFusion platform technology and strengthen its team to capitalize on near and long-term opportunities.

Management Comments

• "Our first weeks as a public company have been extremely productive, and our continued execution brings us closer to achieving our immediate strategic goal of developing a portfolio of potential best-in-class products in eczema and onychomycosis." Bradley Burnam, Founder and Chief Executive Officer.
• "We look forward to seeing data from our lead program in moderate to severe eczema in early 2026, which will inform our development pathway." Bradley Burnam, Founder and Chief Executive Officer.
• "Partnerships like this [Medline agreement] will generate revenues for us without significant capital investment. This revenue will allow us to offset some of the costs, given our modest burn rate, as we focus our internal efforts on high-value drug development programs." Bradley Burnam, Founder and Chief Executive Officer.
• "We have also been steadily strengthening our Board and executive team and have added two new Board members and a capital markets veteran as Vice President of Corporate Communications recently. We will continue to add to our team ensuring we are positioned to capitalize on our near and long-term opportunities." Bradley Burnam, Founder and Chief Executive Officer.

Industry Context

Turn Therapeutics operates in the highly competitive biotechnology sector, specifically focusing on dermatology, wound care, and infectious disease. The Medline agreement positions the company to leverage its PermaFusion platform for broader market penetration in medical-surgical products, a common strategy for clinical-stage companies to generate non-dilutive revenue. The commencement of a new eczema clinical trial aligns with ongoing industry efforts to address significant unmet needs in dermatological conditions, while the vaccine stability data highlights innovation in global health initiatives, a growing area of focus for biotechs.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value through strategic partnerships, pipeline advancement, and access to public funding, balanced against increased short-term losses due to listing costs.
• Employees: Strengthening of the executive team and potential for growth could lead to expanded opportunities.
• Customers/Patients: Advancement of clinical programs in eczema and onychomycosis, and global health initiatives for vaccine delivery, could lead to new treatment options.
• Partners (Medline): Establishment of a long-term collaboration for product development and commercialization.

Next Steps

• Release data from the lead program in moderate to severe eczema in early 2026.
• Continue to develop global relationships to leverage the PermaFusion platform technology.
• Continue to add to the Board and executive team.
• Further development, manufacture, and commercialization of products leveraging the PermaFusion platform with Medline.

Key Dates

Recommendation

While the company reported increased net losses for the quarter, this was largely attributable to one-time costs associated with its successful NASDAQ direct listing, which is a significant positive for future capital access. The strategic global partnership with Medline, new board appointments, and the commencement of a key eczema clinical trial represent substantial progress in the company's development and commercialization strategy. However, the company remains clinical-stage with future data readouts (early 2026 for eczema program) and execution risks. The current financial results reflect investment in growth and public market entry rather than operational profitability. A 'hold' recommendation is appropriate to observe the outcomes of the ongoing clinical trials and the initial revenue generation from the Medline partnership before making a more definitive investment decision.

Keywords

biotechnology, dermatology, wound care, infectious disease, eczema, onychomycosis, vaccine delivery, PermaFusion, Medline, NASDAQ listing, clinical trial, Q3 2025 earnings, biopharma